Novartis wins FDA’s breakthrough tag for lung cancer hopeful

 Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-wins-FDA-s-breakthrough-tag-for-lung-cancer-hopeful-29167013/?countview=0